Lancet Review Questions IVF Add-Ons, Finds Little Evidence of Success

A major international review published in The Lancet Obstetrics, Gynaecology & Women's Health has raised fresh concerns about the effectiveness of many treatments commonly offered alongside In Vitro Fertilisation (IVF). The study found that most IVF "add-ons" either fail to improve fertility outcomes or lack sufficient scientific evidence to demonstrate meaningful benefits.

The findings have sparked renewed debate about patient awareness, treatment costs, and evidence-based fertility care, particularly in countries like India where infertility affects millions and IVF treatment has become increasingly common.

What Are IVF Add-Ons?

IVF add-ons are additional procedures, medications, tests, or technologies offered alongside standard IVF treatment. These interventions are often marketed as methods that may increase the chances of pregnancy, improve embryo implantation, or reduce the risk of miscarriage.

Common IVF Add-Ons Include:

• Embryo glue
• Endometrial scratching
• Assisted hatching
• Time-lapse embryo imaging
• Immunological therapies
• Genetic testing in selected cases
• Various hormonal supplements
• Specialized laboratory techniques

While some add-ons have specific medical indications, many are routinely offered despite limited evidence regarding their effectiveness.

What Did the Lancet Review Find?

The review examined available scientific evidence surrounding commonly used IVF add-ons and found that most do not consistently improve live birth rates or pregnancy outcomes.

Researchers highlighted that several treatments continue to be offered despite a lack of high-quality clinical evidence proving their benefits.

Key Findings

• Many IVF add-ons have insufficient scientific support.
• Several interventions do not significantly improve fertility outcomes.
• Patients may be paying substantial additional costs without clear benefits.
• More rigorous clinical trials are needed.
• Evidence-based counselling remains essential.

The findings have prompted experts to call for greater transparency in fertility treatment practices.

Why This Matters for India

The review carries particular significance for India, where infertility is estimated to affect around 2.8 crore people.

Every year, approximately 3 to 3.5 lakh IVF cycles are performed across the country, making India one of the world's largest fertility treatment markets.

Growing Demand for IVF

Several factors have contributed to increasing IVF demand:

• Delayed parenthood
• Lifestyle changes
• Rising infertility awareness
• Improved access to fertility clinics
• Advances in reproductive medicine

As the fertility industry expands, questions regarding treatment effectiveness and patient information have become increasingly important.

The Financial Burden of IVF Add-Ons

IVF treatment is already a significant financial commitment for many families.

Additional procedures can substantially increase overall treatment costs.

Why Cost Concerns Matter

Patients often face:

• Multiple treatment cycles
• Expensive medications
• Additional laboratory procedures
• Repeated consultations
• Emotional and financial stress

When add-ons are offered without strong supporting evidence, concerns arise about whether patients are receiving value for the additional expense.

The Importance of Evidence-Based Fertility Care

Medical experts increasingly emphasize the importance of evidence-based treatment decisions.

Evidence-based care means that medical interventions should be supported by reliable scientific research demonstrating both safety and effectiveness.

In fertility medicine, this approach is especially important because patients are often emotionally vulnerable and willing to explore any option that might improve their chances of success.

Benefits of Evidence-Based Treatment

• Better patient outcomes
• Reduced unnecessary expenses
• Improved transparency
• Greater trust between doctors and patients
• More informed decision-making

Are All IVF Add-Ons Ineffective?

Not necessarily.

Experts caution that the review does not suggest every add-on lacks value. Some interventions may be beneficial in specific medical situations or for selected patient groups.

The main concern is that many treatments are widely offered without sufficient evidence to justify routine use for all patients.

This highlights the importance of individualized treatment planning rather than a one-size-fits-all approach.

Questions Patients Should Ask Before Choosing Add-Ons

Fertility specialists recommend that patients discuss any proposed add-on treatment in detail before proceeding.

Important Questions Include:

• What evidence supports this treatment?
• How much does it cost?
• What are the potential risks?
• Is it recommended for my specific condition?
• Does it improve live birth rates?
• Are there alternative options?

Understanding these factors can help patients make informed decisions.

The Future of Fertility Treatment

The Lancet review is likely to encourage further research into IVF add-ons and their effectiveness.

Experts believe future studies should focus on:

• Large-scale clinical trials
• Long-term outcomes
• Cost-effectiveness analysis
• Patient-centred care
• Personalized fertility treatment strategies

Such research could help identify which interventions genuinely improve outcomes and which offer little benefit.

Why Patient Awareness Is Critical

Infertility treatment can be emotionally challenging, and patients often seek every possible advantage.

However, specialists stress that informed decision-making is essential. Clear communication regarding benefits, limitations, risks, and evidence can help patients avoid unnecessary treatments and focus on interventions with proven value.

Patient education is increasingly being viewed as a crucial part of fertility care.

Conclusion

The latest Lancet review has reignited discussions about the role of IVF add-ons in modern fertility treatment. While IVF remains an important option for millions struggling with infertility, the study suggests that many additional procedures may offer little proven benefit despite their widespread use and cost. As India's fertility sector continues to grow, the findings underscore the need for evidence-based care, transparent patient counselling, and further research to ensure that treatment decisions are guided by science rather than expectation.

FAQ SECTION

Q1. What are IVF add-ons?
IVF add-ons are additional treatments, procedures, or technologies offered alongside standard IVF to potentially improve outcomes.

Q2. What did the Lancet review find?
The review concluded that most IVF add-ons either do not significantly improve fertility outcomes or lack sufficient scientific evidence.

Q3. Does this mean IVF itself is ineffective?
No. The findings relate specifically to additional treatments offered alongside IVF, not IVF as a whole.

Q4. Why are IVF add-ons controversial?
Many add-ons can increase treatment costs despite limited evidence supporting their effectiveness.

Q5. How many IVF cycles take place in India annually?
Approximately 3 to 3.5 lakh IVF cycles are conducted in India each year.

Q6. Should patients avoid all IVF add-ons?
Not necessarily. Some may be appropriate in specific cases, but patients should discuss evidence, costs, and benefits with their fertility specialists.